The pharmaceutical industry won. The hospital industry lost. After a lobbying fight for the ages between the Pharmaceutical ...

The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a ...

On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...

Despite dramatic expansion over the past 34 years, many rural and underserved hospitals continue to face significant financial pressures and closures, underscoring concerns about whether 340B is ...

The 340B drug plan language that was recently added into Senate Bill 494 risks increasing costs for the very patients it purports to help.

Hospital leaders on Tuesday urged Minnesota lawmakers to act quickly to preserve a drug discount program that has kept their ...

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program ...

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

After federal judges blocked HHS’ 340B rebate pilot program from taking effect Jan. 1, HHS is discussing whether to reconsider the drug manufacturers’ plans, according to court documents. On Jan. 7, ...

Hospitals are suing to block a Trump administration pilot that will allow drugmakers to issue post-sale rebates instead of upfront discounts on medications in the 340B drug discount program, arguing ...